News
ICCC
9.93
-0.45%
-0.05
SRK Capital 2026 Semi-Annual Portfolio Update
Seeking Alpha · 6d ago
Weekly Report: what happened at ICCC last week (0914-0918)?
Weekly Report · 6d ago
Weekly Report: what happened at ICCC last week (0907-0911)?
Weekly Report · 09/14 10:16
Weekly Report: what happened at ICCC last week (0831-0904)?
Weekly Report · 09/07 10:10
Weekly Report: what happened at ICCC last week (0824-0828)?
Weekly Report · 08/31 10:17
ImmuCell Stock Falls 8.8% Despite Y/Y Earnings & Sales Growth in Q2
NASDAQ · 08/27 14:10
Weekly Report: what happened at ICCC last week (0817-0821)?
Weekly Report · 08/24 10:18
Weekly Report: what happened at ICCC last week (0810-0814)?
Weekly Report · 08/17 10:18
Immucell Earnings Call: Growth Strong, Margins Under Pressure
TipRanks · 08/15 00:28
*Immucell 2Q Net $1.84M >ICCC
Dow Jones · 08/13 20:05
Press Release: ImmuCell Announces Unaudited Financial Results for the Quarter Ended June 30, 2026
Dow Jones · 08/13 20:05
Press Release: ImmuCell Announces Unaudited -2-
Dow Jones · 08/13 20:05
Weekly Report: what happened at ICCC last week (0803-0807)?
Weekly Report · 08/10 10:14
ImmuCell to Announce Unaudited Financial Results for the Quarter Ended June 30, 2026
Barchart · 08/06 15:05
Weekly Report: what happened at ICCC last week (0727-0731)?
Weekly Report · 08/03 10:13
Weekly Report: what happened at ICCC last week (0720-0724)?
Weekly Report · 07/27 10:17
ImmuCell: First Defense With Better Execution
Seeking Alpha · 07/24 06:45
Weekly Report: what happened at ICCC last week (0713-0717)?
Weekly Report · 07/20 10:14
Biotech Stocks At 52-Week Highs: AMWL, CUE, ICCC, SRRK, FTH
NASDAQ · 07/13 11:17
Weekly Report: what happened at ICCC last week (0706-0710)?
Weekly Report · 07/13 10:16
More
Webull provides a variety of real-time ICCC stock news. You can receive the latest news about Immucell through multiple platforms. This information may help you make smarter investment decisions.
About ICCC
ImmuCell Corporation is an animal health company. The Company is engaged in the development, acquisition, manufacture, and sale of products that improve the health and productivity of dairy and beef cattle. It operates in two business segments: Scours and Mastitis. The Scours segment is engaged in manufacturing and selling First Defense, a product used to prevent scours in newborn calves. The Mastitis segment includes products called California Mastitis Test and Re-Tain. Re-Tain, a novel treatment for subclinical mastitis in dairy cows, is in the late stages of development. The First Defense product line provides bovine antibodies that newborn calves need but are unable to produce on their own immediately after birth. Its product line extension, Tri-Shield First Defense, is the first calf-level, passive antibody product providing immediate immunity against each of the three causes of calf scours (E. Coli, coronavirus, and rotavirus).